LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Gastric Cancer Detected Through Exhaled Breath

By LabMedica International staff writers
Posted on 27 Apr 2015
Print article
Image: Gas chromatography linked to mass spectrometry apparatus (Photo courtesy of the Hebrew University).
Image: Gas chromatography linked to mass spectrometry apparatus (Photo courtesy of the Hebrew University).
A new type of technology that senses minute changes in the levels of particular compounds in exhaled breath accurately identifies high risk changes which herald the development of stomach cancer.

The technology, known as nanoarray analysis, could be used not only to test for the presence of stomach cancer, but also to monitor those at high risk of subsequently developing the disease as stomach cancer rarely causes symptoms in its early stages, making it hard to detect.

Scientists at the Israel Institute of Technology (Haifa, Israel;) and their colleagues collected 968 breath samples from 484 patients, including 99 with gastric cancer, for two different analyses. The participants had fasted for 12 hours prior to the breath samples being taken and had refrained from smoking for at least three hours beforehand. In addition, subjects were tested for infection with Helicobacter pylori infection, an established risk factor for stomach cancer, and their smoking and drinking habits were analyzed.

The first sample was analyzed by gas chromatography linked to mass spectrometry (GCMS) and the second by cross-reactive nanoarrays combined with pattern recognition. The GCMS analysis that measures the levels of volatile organic compounds (VOCs) identified 130 VOCs in participants' exhaled breath. On comparing the breath samples of participants with stomach cancer with those of participants who had changes in VOC levels considered to be precancerous, the scientists identified eight distinctive "breath-print" compositions.

On applying the nanoarray technique to the breath samples, the team found it was effectively able to distinguish between breath-print compositions in participants with stomach cancer and those at low and high risk of the condition. The method achieved 73% sensitivity, 98% specificity and 92% accuracy, according to the results. While GCMS technology is unable to be used for stomach cancer screening due to its high cost and complexity, the scientists say nanoarray analysis may be a highly accurate and cheaper alternative. The study was published on April 13, 2015, in the journal Gut.

Related Links:

Israel Institute of Technology


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more